MASTER DAPT is the largest multi-center randomized controlled study on the use of short duration of dual antiplatelet therapy (DAPT) in high bleeding risk patients following stenting procedures with Ultimaster™ Family DES.

MASTER DAPT study is sponsored by the European Cardiovascular Research Institute (ECRI, Rotterdam, The Netherlands) and supported with a restricted research grant by Terumo Europe. The study is managed by global CROs and data management groups (CERC, Paris, France, Cardialysis, Rotterdam, The Netherlands, CV quest. Co. Ltd., Tokyo, Japan and CTU, Bern, Switzerland).

Do you need more info about this product?

Our sales representatives are here for you.

Send us a message

First name *

Last name *

Function

Company *

Country *

E-mail address *

Question *

I have read and accept Terumo Privacy And Cookies Policy and the Terms Of Use*

I wish to receive information and marketing updates from Terumo.

* mandatory fields

Thank you for contacting us!

We typically respond within 2 business days and will come back to you as soon as possible.

Are you a healthcare professional?

This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public

For Pharmaceutical Professionals interested in our B2B products portfolio, please visit Terumo Pharmaceutical Solutions.

Discover MASTER DAPT

MASTER DAPT is the largest multi-center randomized controlled study on the use of short duration of dual antiplatelet therapy (DAPT) in high bleeding risk patients following stenting procedures with Ultimaster™ Family DES.

Abbreviated vs prolonged DAPT

Worldwide study

Patient population

Do you need more info about this product?

Send us a message

Are you a healthcare professional?